Evidence map›Paper›PMID 42396333›Full record

ArticlemedRxiv : the preprint server for health sciences2026

The Target ALS Global Natural History Study: Cross-platform proteomics to accelerate biofluid biomarker and drug target discovery in amyotrophic lateral sclerosis.

Daisuke Yasui, Daniel Weatherill, Laura Dugom, Sophia Weiner, Lathika Gopalakrishnan, Huy Tran, Björn Oskarsson, Kyra Nagle, Timothy Miller, Gilbert Gutierrez and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Daisuke YasuiDepartment of Neurology, Washington University in St Louis, St Louis, MO, USA.ORCID 0009-0004-4461-3287
Daniel WeatherillTarget ALS Foundation, New York, NY, USA.
Laura DugomTarget ALS Foundation, New York, NY, USA.
Sophia WeinerDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Lathika GopalakrishnanDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Huy TranDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Björn OskarssonDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Kyra NagleDepartment of Neurology, Washington University in St Louis, St Louis, MO, USA.
Timothy MillerDepartment of Neurology, Washington University in St Louis, St Louis, MO, USA.
Gilbert GutierrezDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
John RavitsDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
Benjamin HooverDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Matthew HarmsDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Neil ShneiderDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Lizzi NeylonTarget ALS Foundation, New York, NY, USA.
Whitney DaileyDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Shafeeq LadhaDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Cassandra HolmesDepartment of Neurology, Georgetown University Medical Center, Washington, DC, USA.
Joseph LeeDepartment of Neurology, Georgetown University Medical Center, Washington, DC, USA.
Nicholas StreicherDepartment of Neurology, Georgetown University Medical Center, Washington, DC, USA.
Shakti NayarDepartment of Neurology, Georgetown University Medical Center, Washington, DC, USA.
Brent T HarrisDepartment of Neurology, Georgetown University Medical Center, Washington, DC, USA.
Manish RaisinghaniTarget ALS Foundation, New York, NY, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Johan GobomDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Amy EastonTarget ALS Foundation, New York, NY, USA.
Robert BowserDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Cindy V LyDepartment of Neurology, Washington University in St Louis, St Louis, MO, USA.

Funding

Access for All in ALS (ALL ALS) West Clinical Coordinating Center OT2NS136939 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI ROBERT P BOWSER, BRENT T HARRIS · 2023 to 2026
$76.5M
Identifying mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosisR01NS138499 · NINDS · WASHINGTON UNIVERSITY · PI Cindy V Ly · 2024 to 2026
$1.6M
NINDS NIH HHS OT2 NS136939NINDS NIH HHS R01 NS138499
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly progressive neurodegenerative disease of motor neurons for which therapeutics are limited. Improved biomarkers are imperative to improve patient care and therapeutic development. Here, we employed 35-plex isobaric tandem mass tag labeling based on isobutyl-proline reporter group (TMTpro) to perform unbiased proteomic analysis of cerebrospinal fluid (CSF) and plasma from control (n= 28, n= 31) and sporadic ALS (sALS) (n= 39, n= 41), from the Target ALS Global Natural History Study (TALS GNHS). We identified 2,875 proteins in CSF and 1,118 proteins in plasma and identified known and novel differentially expressed proteins (DEPs) between controls and sALS, some of which were orthogonally validated using immunoassay. Comparison of TMTpro-MS and Olink proximity extension assay proteomics revealed common and non-overlapping differentially expressed proteins illustrating strengths unique to each platform. This initial cross-sectional proteomic study of biofluids from the TALS GNHS, with unrestricted availability of study results to the research community, highlights the potential of this resource as a potent platform for ALS biomarker discovery.

Identifiers

PMID42396333
PMCPMC13321115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.